Takeda is paying for certain transition expenses incurred by Affymax for the month of April in connection with the transfer of Omontys and the FDA investigation to Takeda. Noone knows what else Affymax has promised to perform or undertake in connection with the milestone/royalty ageement. Should Affymax wish to emerge as a viable company after any Chapter 11 reorganization, it may have to support the Takeda investigation. Remember, the public policies behind Chapter 11 are not to protect shareholder who are last on the list of claimants. The public policy is to rehabilitate the bankrupt entity so it may emerge from Chapter 11 to do business, hire employees and contribute to the economy.